Irish literature and music is full of tales of trouble, sorrow and woe, and Allied Irish Banks (NYSE:AIB) is trying hard not to become part of that canon. Allied Irish has been walloped by the same overheated markets and poor underwriting decisions that have hammered many Western banks, and Allied Irish is scrambling to shore up its capital. Although asset sales will help, Allied Irish could be in for a long slog as what the company needs most of all is a healthy operating environment, and that looks to be a ways off.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

A Housing Bubble Taken to "11"
Once called the "Celtic tiger", Ireland hit the rocks harder than most other Western economies. Not only were there bubbles in residential and commercial real estate, but the export-driven economy has taken a serious hit from the decline in demand throughout Europe. Allied Irish found itself in a situation where it had become dependent upon wholesale funding to fill the gap between loan demand and deposit supply, and then found its loan book going very bad very quickly. Even though Ireland has set up a government-sponsored "bad bank" to take on bad loans, Allied Irish still saw one-quarter of its loans in some state of concern at the end of its June quarter. AIB reports credit in "watch", "vulnerable" and "impaired" categories, and the 25% refers to the combination of all three. (For more on housing bubbles, check out 5 Steps Of A Bubble.)

Selling the Parts
With no one expecting a quick turnaround in the bank's core business, AIB has turned its efforts to raise capital by selling valuable assets. AIB announced on Friday that it had selected the bid of Spain's Santander (NYSE:STD) over those of France's BNP Paribas and a Polish bank for its 70% stake in Bank Zachodni. AIB will be getting about $3.7 billion from Santander for this sizable piece of Poland's third-largest bank.

Even more interesting could be the disposition of AIB's 22% stake in Buffalo-based M&T Bank (NYSE:MTB). Santander was quite clear earlier this year about wanting to buy this stake and the rest of M&T, but the American bank was not keen to sell. There is ample logic for this deal, and Santander could probably pay up to $100 a share for MTB and still get decent value.( For related reading, check out The Evolution Of Banking.)

AIB's Alternatives
If M&T refuses to sell itself entirely, the options for the AIB stake get a bit more interesting. Perhaps a patient company like US Bancorp (NYSE:USB) would be interested, with the idea of maybe "softening up" M&T management's feelings towards a full merger down the line. Likewise, the same could apply for other banks like PNC (NYSE:PNC), though it would be a much larger deal for PNC. Investors should not expect banks like Wells Fargo (NYSE:WFC) or Bank Of America (NYSE:BAC) to jump in, though - their size puts any potential deals under even greater scrutiny and it is unlikely that the government is inclined to create even more "too big to fail" entities.

Of course, none of this is to say that AIB could not sell its M&T stake to another European bank that would be willing to just sit tight as a major investor and not make a play for the whole bank. It would certainly seem that that would be M&T's preference.

The Bottom Line
What should investors take away from the AIB saga? Well, the notion that "growth that seems too good to last" probably will not last is true, but maybe cliché at this point. Unfortunately, AIB looked like a good bank for so long that many investors got lulled into a false sense of security. There were certainly warning signs along the way, and maybe that is the ultimate takeaway: however good a company has been in the past, investors must keep a close eye on current operating conditions. After all, no company is so good that things cannot go wrong.

There is still hope for AIB, but it is going to be a long, hard and uncertain road. At this point, it is certainly not a stock for the faint of heart. (For related reading, see Operational Risk: A Must-Know For Investors.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
  7. Stock Analysis

    Analyzing Porter's Five Forces on Under Armour (UA)

    Learn about Under Armour and how it differentiates itself in the competitive athletic apparel industry in light of the Porter's Five Forces Model.
  8. Stock Analysis

    The Biggest Risks of Investing in Qualcomm Stock (QCOM, BRCM)

    Understand the long-term fundamental risks related to investing in Qualcomm stock, and how financial ratios also play into the investment consideration.
  9. Stock Analysis

    The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

    Learn the largest risks to investing in Johnson & Johnson through fundamental analysis and other potential risks. Also discover how JNJ compares to its peers.
  10. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  1. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  2. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  3. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  4. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  5. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
  6. What is the formula for calculating earnings per share (EPS)?

    Earnings per share (EPS) is the portion of a company’s profit that is allocated to each outstanding share of common stock, ... Read Full Answer >>
Trading Center